Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01492088

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Relapsed or Refractory Anaplastic Large-cell Lymphoma Relapsed or Refractory Hodgkin Lymphoma

Interventions Brentuximab vedotin

Updated 12 times since 2017 Last updated: May 7, 2024 Started: Apr 16, 2012 Primary completion: Oct 12, 2016 Completion: Apr 12, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01492088, this PHASE1/PHASE2 trial focuses on Relapsed or Refractory Anaplastic Large-cell Lymphoma and Relapsed or Refractory Hodgkin Lymphoma and remains completed. Sponsored by Millennium Pharmaceuticals, Inc., it has been updated 12 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Jun 2024 [monthly]

Completed PHASE1_PHASE2

▶ Show 7 earlier versions

Dec 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Dec 2018 [monthly]

Completed PHASE1_PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Jul 2017 — May 2018 [monthly]

Active Not Recruiting PHASE1_PHASE2

Phase: PHASE2 → PHASE1_PHASE2
Apr 2017 — Jul 2017 [monthly]

Active Not Recruiting PHASE2

Status: Completed → Active Not Recruiting
Feb 2017 — Apr 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Millennium Pharmaceuticals, Inc.

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Barcelona, Spain , Berlin, Germany , Bordeaux, France , Frankfurt, Germany , Giessen, Germany , Halle, Germany , Houston, United States , Kansas City, United States , London, United Kingdom and 8 more locations